Signal Transduction and Targeted Therapy

Article	Citations
Pyroptosis: mechanisms and diseases	1076
Inflammation and tumor progression: signaling pathways and targeted intervention	1001
The JAK/STAT signaling pathway: from bench to clinic	941
The role of m6A modification in the biological functions and diseases	931
Microbiota in health and diseases	836
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives	769
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities	737
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells	692
Pattern recognition receptors in health and diseases	685
Therapeutic peptides: current applications and future directions	674
Ferroptosis: mechanisms and links with diseases	647
Viral vector platforms within the gene therapy landscape	646
Antibody drug conjugate: the “biological missile” for targeted cancer therapy	549
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets	527
Targeting PI3K/Akt signal transduction for cancer therapy	506
Copper homeostasis and cuproptosis in health and disease	444
Targeting tumor-associated macrophages to synergize tumor immunotherapy	416
Circulating tumor cells: biology and clinical significance	406
Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity	404
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy	394
Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics	392
SARS-CoV-2 Omicron variant: recent progress and future perspectives	381
A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome	380
Stem cell-based therapy for human diseases	380
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments	367

The signal pathways and treatment of cytokine storm in COVID-19	365
Notch signaling pathway: architecture, disease, and therapeutics	365
Extracellular matrix and its therapeutic potential for cancer treatment	361
Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development	356
Targeting macrophages in cancer immunotherapy	354
KRAS mutation: from undruggable to druggable in cancer	353
Lactate metabolism in human health and disease	349
Macrophages in immunoregulation and therapeutics	341
DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy	340
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention	338
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer	328
Osteoarthritis: pathogenic signaling pathways and therapeutic targets	319
Liquid–liquid phase separation in human health and diseases	313
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer	308
G protein-coupled receptors: structure- and function-based drug discovery	305
Regulated cell death (RCD) in cancer: key pathways and targeted therapies	292
Signaling pathways and targeted therapy for myocardial infarction	281
Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches	276
Wnt/β-catenin signaling in cancers and targeted therapies	273
Targeting circular RNAs as a therapeutic approach: current strategies and challenges	262
Advances in COVID-19 mRNA vaccine development	261
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1	258
Targeted protein degradation: mechanisms, strategies and application	254
mRNA-based therapeutics: powerful and versatile tools to combat diseases	250
The blood–brain barrier: Structure, regulation and drug delivery	245
The secretion profile of mesenchymal stem cells and potential applications in treating human diseases	244
Neoantigens: promising targets for cancer therapy	241
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy	235
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions	232
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions	229
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy	227
NAD+ metabolism, stemness, the immune response, and cancer	226
Radiotherapy combined with immunotherapy: the dawn of cancer treatment	225
The sirtuin family in health and disease	225
Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents	221
Targeting integrin pathways: mechanisms and advances in therapy	220
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling	220
Emerging new therapeutic antibody derivatives for cancer treatment	218
Trends in insulin resistance: insights into mechanisms and therapeutic strategy	218
From purines to purinergic signalling: molecular functions and human diseases	215
Role of neuroinflammation in neurodegeneration development	211
HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation	209
COVID-19 vaccine development: milestones, lessons and prospects	208
Alternative splicing and cancer: a systematic review	207
Angiogenic signaling pathways and anti-angiogenic therapy for cancer	202
Mutations of MSH5 in nonobstructive azoospermia (NOA) and rescued via in vivo gene editing	201
T cell receptor (TCR) signaling in health and disease	197
Targeting TGFβ signal transduction for cancer therapy	196
Inflammation and aging: signaling pathways and intervention therapies	194
SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance	193

Epigenetic regulation of aging: implications for interventions of aging and diseases	186
Roles and mechanisms of exosomal non-coding RNAs in human health and diseases	184
Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial	181
SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration	181
Protein kinase CK2: a potential therapeutic target for diverse human diseases	181
Structural biology of SARS-CoV-2: open the door for novel therapies	176
SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2	175
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy	175
Targeting non-coding RNAs to overcome cancer therapy resistance	175
Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future	171
Small molecule metabolites: discovery of biomarkers and therapeutic targets	168
Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway	166
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response	165
Intercellular mitochondrial transfer as a means of tissue revitalization	165
COVID-19 in early 2021: current status and looking forward	165
Targeting p53 pathways: mechanisms, structures and advances in therapy	162
The Hippo signalling pathway and its implications in human health and diseases	161
The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives	161
Targeting fibrosis: mechanisms and clinical trials	158
The BET family in immunity and disease	156
The biological applications of DNA nanomaterials: current challenges and future directions	153
T cells in health and disease	153
Human organoids in basic research and clinical applications	151
CRISPR/Cas9 therapeutics: progress and prospects	150
Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events	149
Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies	148
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics	147
Recent progress in targeted delivery vectors based on biomimetic nanoparticles	146
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response	145
Signal pathways of melanoma and targeted therapy	145
HIF-1α promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19	145
COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms	144
Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations	142
Mitochondrial dynamics in health and disease: mechanisms and potential targets	141
Inflammation, epigenetics, and metabolism converge to cell senescence and ageing: the regulation and intervention	141
Signaling pathways in obesity: mechanisms and therapeutic interventions	139
AlphaFold2 and its applications in the fields of biology and medicine	136
Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson’s disease by regulating gut microbiota	134
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets	133
Kidney fibrosis: from mechanisms to therapeutic medicines	133
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)	133
Nanomedicine in cancer therapy	132
Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer	131
Bioactive potential of natural biomaterials: identification, retention and assessment of biological properties	131
Vaccine adjuvants: mechanisms and platforms	130
Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion	130
Immunosenescence: molecular mechanisms and diseases	127
Artificial intelligence in cancer target identification and drug discovery	126
Inflammasomes as therapeutic targets in human diseases	125
Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics	125
The glycosylation in SARS-CoV-2 and its receptor ACE2	122
Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials	121
Molecular regulations of circadian rhythm and implications for physiology and diseases	121
Colorectal liver metastasis: molecular mechanism and interventional therapy	120
Smart nanoparticles for cancer therapy	120
Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis	119
A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair	118
The STING1 network regulates autophagy and cell death	118
RNA modifications: importance in immune cell biology and related diseases	117
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients	116
Mesenchymal stem cell-derived small extracellular vesicles mitigate oxidative stress-induced senescence in endothelial cells via regulation of miR-146a/Src	114
Monkeypox: epidemiology, pathogenesis, treatment and prevention	113
Signaling pathways and intervention therapies in sepsis	112
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer	111
Omicron: increased transmissibility and decreased pathogenicity	110
Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease	110
A systemic and molecular study of subcellular localization of SARS-CoV-2 proteins	109
Signaling pathways of chronic kidney diseases, implications for therapeutics	109
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy	109
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)	108
Signaling pathways in rheumatoid arthritis: implications for targeted therapy	107
Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression	107
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies	107
Ketogenic diet alleviates colitis by reduction of colonic group 3 innate lymphoid cells through altering gut microbiome	107
Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages	106
Alternative approaches to target Myc for cancer treatment	106
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy	104
Cytosolic DNA sensing by cGAS: regulation, function, and human diseases	104
RNA-induced liquid phase separation of SARS-CoV-2 nucleocapsid protein facilitates NF-κB hyper-activation and inflammation	104
Spinal cord injury: molecular mechanisms and therapeutic interventions	104

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends	103
CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis	103
Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy	102
Natural killer cell homing and trafficking in tissues and tumors: from biology to application	102
Ketogenic diets inhibit mitochondrial biogenesis and induce cardiac fibrosis	100
ACE2-independent infection of T lymphocytes by SARS-CoV-2	100
The role of histone modifications: from neurodevelopment to neurodiseases	99
Engineered exosomes from different sources for cancer-targeted therapy	97
Functional hair follicle regeneration: an updated review	97
Endoplasmic reticulum stress: molecular mechanism and therapeutic targets	96
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19	95
Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines	94
Targeting ferroptosis opens new avenues for the development of novel therapeutics	94
Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions	93
Targeting epigenetic regulators to overcome drug resistance in cancers	93
Signaling pathways and therapeutic interventions in gastric cancer	93
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study	93
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies	92
Unique and complementary suppression of cGAS-STING and RNA sensing- triggered innate immune responses by SARS-CoV-2 proteins	90
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer	89
SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies	89
Spatiotemporal control of CRISPR/Cas9 gene editing	89
Targeting lysosomes in human disease: from basic research to clinical applications	89
A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity	88
NAT10 promotes gastric cancer metastasis via N4-acetylated COL5A1	88
Clinical and translational values of spatial transcriptomics	87
The olfactory route is a potential way for SARS-CoV-2 to invade the central nervous system of rhesus monkeys	87
ALOX15-launched PUFA-phospholipids peroxidation increases the susceptibility of ferroptosis in ischemia-induced myocardial damage	86
NF-κB in biology and targeted therapy: new insights and translational implications	85
Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions	85
The mitophagy pathway and its implications in human diseases	85
Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes	84
Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine	84
GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages	83
Emerging phagocytosis checkpoints in cancer immunotherapy	83
Ribosome biogenesis in disease: new players and therapeutic targets	82
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective	82
SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules	82
Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy	81
Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome	80
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)	80
Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment	80
Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting	80
m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance	79
Patient-derived xenograft models in cancer therapy: technologies and applications	78
Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients	77
Neurological complications and infection mechanism of SARS-CoV-2	76
The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing	75
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management	75
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications	75
Oncolytic virotherapy: basic principles, recent advances and future directions	75
Dynamic blood single-cell immune responses in patients with COVID-19	75
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets	74
Liquid–liquid phase separation in tumor biology	74
Omicron adopts a different strategy from Delta and other variants to adapt to host	74
POD Nanozyme optimized by charge separation engineering for light/pH activated bacteria catalytic/photodynamic therapy	74
TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases	74
Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need	73
Targeting polarized phenotype of microglia via IL6/JAK2/STAT3 signaling to reduce NSCLC brain metastasis	72
The key roles of cancer stem cell-derived extracellular vesicles	72
Amino acid metabolism in health and disease	72
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies	72
Temporal and spatial cellular and molecular pathological alterations with single-cell resolution in the adult spinal cord after injury	72
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants	72
Cardiomyocyte-specific knockout of ADAM17 ameliorates left ventricular remodeling and function in diabetic cardiomyopathy of mice	71
N501Y mutation imparts cross-species transmission of SARS-CoV-2 to mice by enhancing receptor binding	71
Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications	71
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia	70
Application of 3D bioprinting in the prevention and the therapy for human diseases	69
Pathogenesis of allergic diseases and implications for therapeutic interventions	69
CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma	69
Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer	69
A dual-role of SARS-CoV-2 nucleocapsid protein in regulating innate immune response	69
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19	68
Not only ACE2—the quest for additional host cell mediators of SARS-CoV-2 infection: Neuropilin-1 (NRP1) as a novel SARS-CoV-2 host cell entry mediator implicated in COVID-19	67
Mesenchymal stem cell therapy for severe COVID-19	67
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials	67
Cryo-EM advances in RNA structure determination	66
Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3	66
Clinical applications of stem cell-derived exosomes	65
Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19	65
Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster	65
Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects	64
Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets	63
Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence	63
SARS-CoV-2 spike L452R mutation increases Omicron variant fusogenicity and infectivity as well as host glycolysis	62
Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota	62
Dietary regulation in health and disease	62
Small molecules in the treatment of COVID-19	62
SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer	61
The regulation of protein translation and its implications for cancer	61
Extracellular vesicles as tools and targets in therapy for diseases	61
The adaptive transition of glioblastoma stem cells and its implications on treatments	61
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases	60
COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factors	60